Immuneering (IMRX) Cash from Financing Activities (2020 - 2026)
Immuneering (IMRX) posted quarterly Cash from Financing Activities of $180760.0 for Q1 2026, down 98.69% year-over-year from $13.8 million in Q1 2025, and up 150.56% quarter-over-quarter from -$357523.0 in Q4 2025.
Immuneering (IMRX) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Immuneering's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $180760.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 98.69% year-over-year to $180760.0; the TTM figure through Mar 2026 stood at $213.0 million (up 1074.32% YoY), while the FY2025 annual figure was $226.6 million, up 4172.32% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $180760.0, up from -$357523.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $213.2 million in Q3 2025, with the low at -$357523.0 in Q4 2025.
- The 5-year median for Cash from Financing Activities is $104272.0 (2022), against an average of $16.3 million.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities tumbled 2556.14% in 2022, then jumped 101297.86% in 2023.
- Immuneering's Cash from Financing Activities stood at -$184677.0 in 2022, then soared by 104.24% to $7835.0 in 2023, then plunged by 623.14% to -$40988.0 in 2024, then tumbled by 772.26% to -$357523.0 in 2025, then soared by 150.56% to $180760.0 in 2026.
- Business Quant data shows IMRX's Cash from Financing Activities at $180760.0 in Q1 2026, -$357523.0 in Q4 2025, and $213.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | 24,608.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24,608.00 |
| Jun 30, 2026 | 24,608.00 |
| Mar 31, 2026 | 180,760.00 |
| Mar 31, 2026 | 180,760.00 |
| Dec 31, 2025 | -357,523.00 |
| Dec 31, 2025 | -357,523.00 |
| Sep 30, 2025 | 213.19 Mn |
| Sep 30, 2025 | 213.19 Mn |
| Jun 30, 2025 | -61,958.00 |
| Jun 30, 2025 | -61,958.00 |
| Mar 31, 2025 | 13.81 Mn |
| Mar 31, 2025 | 13.81 Mn |
| Dec 31, 2024 | -40,988.00 |
| Dec 31, 2024 | -40,988.00 |
| Sep 30, 2024 | 4.36 Mn |
| Sep 30, 2024 | 4.36 Mn |
| Mar 31, 2024 | 979,923.00 |
| Mar 31, 2024 | 979,923.00 |
| Dec 31, 2023 | 7,835.00 |
| Dec 31, 2023 | 7,835.00 |